Hyperfine (HYPR) Cash from Operations Growth (3y) (2024 - 2026)
Hyperfine (HYPR) Cash from Operations Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.90 Bn | 176.61 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.85 Bn | 125.97 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.77 Bn | 99.55 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.39 Bn | 66.93 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.50 Bn | 44.83 Bn | 1.29 Bn | -48.14% |
| 6 | GE HealthCare Technologies | 28.36 Bn | 26.08 Bn | 1.98 Bn | -14.75% |
| 7 | Dexcom | 28.36 Bn | 27.24 Bn | 750.30 Mn | 50.11% |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.48 Bn | 22.35 Bn | 2.07 Bn | 0.50% |
| 10 | Hyperfine | 94.10 Mn | 52.82 Mn | 1.98 Mn | 12.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.60% |
| Dec 31, 2025 | 30.25% |
| Sep 30, 2025 | 24.15% |
| Jun 30, 2025 | 22.37% |
| Mar 31, 2025 | 30.28% |
| Dec 31, 2024 | 22.76% |
| Sep 30, 2024 | 5.03% |
| Jun 30, 2024 | 6.87% |
| Mar 31, 2024 | -18.67% |